Biotech scaled

GLP-1 agonists

GLP-1 agonists have revolutionized type 2 diabetes and obesity treatment, shifting paradigm from symptomatic glycemic control to weight loss-driven metabolic improvement, with >$20B annual market value by 2026.

What to watch next

Retatrutide NDA filing and approval (late 2026-2027), broader expansion into cardiovascular and renal disease indications, and emergence of next-generation agonists with improved efficacy/tolerability profiles.

Key sub-ideas & techniques

• Semaglutide (mono GLP-1) — Once-weekly semaglutide (Ozempic / Wegovy) delivered ~15% weight loss in obesity trials and showed ~20% MACE reduction in SELECT — the first obesity drug with hard cardiovascular outcome data. [source]
• Tirzepatide (dual GIP/GLP-1) — Lilly's tirzepatide (Mounjaro / Zepbound) hit ~22.5% weight loss at top dose in SURMOUNT-1, leapfrogging semaglutide and triggering the obesity-drug supply crisis of 2023–24. [source]
• Retatrutide (triple agonist) — Retatrutide (GIP/GLP-1/glucagon) showed ~24% weight loss in Phase 2 and ~71 lbs / 28% in early Phase 3 — likely setting the new ceiling and adding glucagon-driven energy expenditure to the mechanism. [source]
• Oral GLP-1s — Oral semaglutide and Lilly's orforglipron are removing the injection barrier and could expand the market by an order of magnitude — manufacturable as small molecules without peptide-supply bottlenecks. [source]
• Indication expansion — GLP-1s now have approvals or strong RCT data in cardiovascular disease (SELECT), kidney disease (FLOW), MASH/MASLD, obstructive sleep apnea (SURMOUNT-OSA), and emerging signals in Alzheimer's and addiction. [source]
• Amylin analogs as next-wave obesity therapeutics — Amylin-receptor agonists (e.g. petrelintide) restore leptin sensitivity to induce satiety with markedly better GI tolerability than incretins, enabling co-formulation with GLP-1/GIP agonists like enicepatide. [source]
• Amylin agonism and muscle-preserving obesity combinations — Beyond GLP-1: selective amylin receptor agonists and combos engineered to preserve lean mass (e.g., GLP-1 + myostatin inhibition) became a dominant ADA 2026 theme, addressing the lean-mass-loss limitation of incretins. [source]

Current frontier

• Retatrutide (GIP/GLP-1/glucagon triple agonist) showed 28.7% weight loss and A1C reductions up to 2.0% in Phase 3 TRANSCEND-T2D-1 trial (announced March 2026). [source]
• Retatrutide demonstrated 71.2 lbs average weight loss and substantial osteoarthritis pain relief in Phase 3 obesity trial (announced February 2026), with 7 additional Phase 3 trials expected to complete in 2026. [source]
• Zepbound (tirzepatide) received additional FDA approval for moderate-to-severe obstructive sleep apnea in obesity (December 2024), marking first medication approved specifically for this indication. [source]
• Semaglutide (Novo Nordisk) is a GLP-1 agonist with 94% homology to native GLP-1, modified with DPP-4 protease-resistant alanine substitution, used at lower doses for Ozempic/Victoza diabetes and higher doses for Wegovy/Saxenda weight loss. [source]
• Oral semaglutide approved by FDA as first GLP-1 pill for weight loss, expanding non-injection delivery options while maintaining efficacy of injectable formulations. [source]
• Triple-agonist retatrutide produces bariatric-surgery-class weight loss (30%+) in a pivotal Phase 3 trial without surgery, redefining the achievable benchmark for obesity pharmacotherapy. [source]

Key people

• Jens Holst Professor Emeritus; Discoverer of GLP-1 hormone · University of Copenhagen [source]
• Mads Krogsgaard Thomsen Chief Scientific Officer · Novo Nordisk [source]
• Lilly Tirzepatide Development Team Vice President of Diabetes Development · Eli Lilly and Company [source]
• Juan Pablo Gonzalez Chief Medical Officer (implied from retatrutide development) · Eli Lilly and Company [source]
• Lars Reinhard R&D leadership; Mounjaro development · Eli Lilly and Company [source]
• Ania M. Jastreboff Professor of Medicine; Director, Yale Y-Weight Obesity Research Center; lead investigator, retatrutide TRIUMPH-1 · Yale University School of Medicine [source]

Startups & labs to watch

• Retatrutide clinical program (Eli Lilly) Eli Lilly and Company · STARTUP · Eli Lilly internal R&D ($3B+ annual pharma R&D) — Triple agonist showing superior efficacy vs. dual agonists; Phase 3 trials ongoing in obesity, type 2 diabetes, osteoarthritis, sleep apnea, MASH; potential NDA filing expected late 2026. [source]
• Oral GLP-1 platform development (Novo Nordisk, Eli Lilly, others) Multiple pharmaceutical companies · STARTUP · Multiple companies with $10B+ combined R&D spending — Oral semaglutide approved; multiple oral GLP-1/GIP agonists in development; expanding accessibility of GLP-1 therapy beyond injection-dependent populations. [source]
• Novo Nordisk semaglutide pipeline expansion Novo Nordisk A/S · STARTUP · Novo Nordisk annual R&D budget ($1B+) — Expanding semaglutide beyond diabetes and obesity into cardiovascular, kidney disease, and MASH indications; LEADER, SUSTAIN, and FLOW trial data expanding label potential. [source]
• Roche obesity portfolio (petrelintide + enicepatide) Roche · LAB · Roche internal R&D (large pharma); petrelintide via Carmot acquisition — Major new entrant validating the amylin pathway; petrelintide Phase 2 data positioned as a core asset alongside enicepatide combinations at ADA 2026. [source]